GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives $3.81 Average Price Target from Brokerages

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) have been given a consensus recommendation of “Hold” by the fifteen ratings firms that are presently covering the company, MarketBeat reports. Three investment analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $3.8125.

Several research analysts recently weighed in on the stock. The Goldman Sachs Group restated a “neutral” rating and set a $3.50 price target on shares of GoodRx in a report on Friday, May 8th. TD Cowen boosted their price target on shares of GoodRx from $3.00 to $4.00 and gave the stock a “buy” rating in a report on Monday, May 11th. Leerink Partners restated an “outperform” rating and set a $3.00 price target on shares of GoodRx in a report on Thursday, February 26th. Citigroup boosted their price target on shares of GoodRx from $3.50 to $4.00 and gave the stock a “buy” rating in a report on Thursday, May 14th. Finally, Weiss Ratings cut shares of GoodRx from a “sell (d+)” rating to a “sell (d)” rating in a report on Wednesday, May 20th.

GoodRx Stock Up 1.4%

GoodRx stock opened at $2.85 on Friday. GoodRx has a fifty-two week low of $1.77 and a fifty-two week high of $5.81. The stock has a market cap of $976.32 million, a PE ratio of 47.51, a price-to-earnings-growth ratio of 1.80 and a beta of 1.61. The firm’s 50-day simple moving average is $2.43 and its 200 day simple moving average is $2.49. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.47 and a current ratio of 1.47.

GoodRx (NASDAQ:GDRX) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.07 earnings per share for the quarter, hitting the consensus estimate of $0.07. GoodRx had a net margin of 2.61% and a return on equity of 7.90%. The business had revenue of $194.01 million for the quarter, compared to analysts’ expectations of $185.40 million. During the same period in the previous year, the company earned $0.09 earnings per share. The firm’s revenue for the quarter was down 4.4% compared to the same quarter last year. Research analysts predict that GoodRx will post 0.17 EPS for the current fiscal year.

Institutional Trading of GoodRx

Hedge funds have recently added to or reduced their stakes in the stock. Quarry LP bought a new stake in GoodRx in the third quarter worth about $33,000. Cetera Investment Advisers bought a new stake in GoodRx in the second quarter worth about $50,000. Boothbay Fund Management LLC bought a new stake in GoodRx in the third quarter worth about $43,000. Meridian Wealth Management LLC bought a new stake in GoodRx in the fourth quarter worth about $29,000. Finally, Shay Capital LLC bought a new stake in GoodRx in the third quarter worth about $47,000. Institutional investors own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.